These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26793871)

  • 1. [Molecular-targeted therapy for prostate cancer].
    Miyake H; Fujisawa M
    Nihon Rinsho; 2016 Jan; 74(1):2-5. PubMed ID: 26793871
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalising the treatment of prostate cancer.
    Gunjur A
    Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic Value of an Integrin Antagonist in Prostate Cancer.
    Philippe CL
    Curr Drug Targets; 2016; 17(3):321-7. PubMed ID: 26648077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.
    Wozney JL; Antonarakis ES
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):581-94. PubMed ID: 24402967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy in the treatment of castration-resistant prostate cancer.
    Derleth CL; Yu EY
    Oncology (Williston Park); 2013 Jul; 27(7):620-8. PubMed ID: 23977754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer proteomics.
    Masters JR
    OMICS; 2011 Mar; 15(3):169-71. PubMed ID: 21319990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
    Hansen AR; Siu LL
    JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted Therapies for Prostate Cancer.
    Petrioli R; Francini E; Fiaschi AI; Laera L; Roviello G
    Cancer Invest; 2015; 33(7):276-85. PubMed ID: 25951372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targets of selenium in prostate cancer prevention (Review).
    Abdulah R; Kobayashi K; Yamazaki C; Koyama H
    Int J Oncol; 2011 Aug; 39(2):301-9. PubMed ID: 21567081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targeted therapies for prostate cancer.
    Macfarlane RJ; Chi KN
    Urol Clin North Am; 2010 Feb; 37(1):105-19, Table of Contents. PubMed ID: 20152524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy in prostate cancer.
    Corcoran NM; Gleave ME
    Histopathology; 2012 Jan; 60(1):216-31. PubMed ID: 22212088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor biomarkers: PSA and beyond.
    Melichar B
    Clin Chem Lab Med; 2012 Nov; 50(11):1865-9. PubMed ID: 23072854
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular pathology and prostate cancer therapeutics: from biology to bedside.
    Rodrigues DN; Butler LM; Estelles DL; de Bono JS
    J Pathol; 2014 Jan; 232(2):178-84. PubMed ID: 24108540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castration-resistant prostate cancer: targeted therapies.
    Leo S; Accettura C; Lorusso V
    Chemotherapy; 2011; 57(2):115-27. PubMed ID: 21430379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
    Heidegger I; Massoner P; Sampson N; Klocker H
    Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibitors in the treatment of prostate cancer.
    Adesunloye BA; Karzai FH; Dahut WL
    Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).
    Toren P; Zoubeidi A
    Int J Oncol; 2014 Nov; 45(5):1793-801. PubMed ID: 25120209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the relaxin hormonal pathway in prostate cancer.
    Neschadim A; Summerlee AJ; Silvertown JD
    Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.